Ocugen (OCGN) Capital Expenditures Growth (1y) (2015 - 2026)
Powered by 
Analysis
Ocugen (OCGN) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -51.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.16% |
| Mar 31, 2026 | -62.50% |
| Dec 31, 2025 | 169.23% |
| Sep 30, 2025 | -82.05% |
| Jun 30, 2025 | -91.62% |
| Mar 31, 2025 | -99.32% |
| Dec 31, 2024 | -99.52% |
| Sep 30, 2024 | -84.93% |
| Jun 30, 2024 | -81.53% |
| Mar 31, 2024 | 45.91% |
| Dec 31, 2023 | 34.49% |
| Sep 30, 2023 | 298.70% |
| Jun 30, 2023 | 183.95% |
| Mar 31, 2023 | 163.83% |
| Dec 31, 2022 | 954.17% |
| Sep 30, 2022 | 278.48% |
| Jun 30, 2022 | 271.86% |
| Mar 31, 2022 | 134.10% |
| Dec 31, 2021 | -23.51% |
| Sep 30, 2021 | 913.64% |